These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 29323298)

  • 1. A metabolic function of FGFR3-TACC3 gene fusions in cancer.
    Frattini V; Pagnotta SM; Tala ; Fan JJ; Russo MV; Lee SB; Garofano L; Zhang J; Shi P; Lewis G; Sanson H; Frederick V; Castano AM; Cerulo L; Rolland DCM; Mall R; Mokhtari K; Elenitoba-Johnson KSJ; Sanson M; Huang X; Ceccarelli M; Lasorella A; Iavarone A
    Nature; 2018 Jan; 553(7687):222-227. PubMed ID: 29323298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
    Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
    Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR3-TACC3 Activates Mitochondrial Respiration via PIN4 Phosphorylation.
    Cancer Discov; 2018 Feb; 8(2):139. PubMed ID: 29330265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
    Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
    Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
    Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic FGFR3 gene fusions in bladder cancer.
    Williams SV; Hurst CD; Knowles MA
    Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
    Zhang Y; Nguyen TTT; Shang E; Mela A; Humala N; Mahajan A; Zhao J; Shu C; Torrini C; Sanchez-Quintero MJ; Kleiner G; Bianchetti E; Westhoff MA; Quinzii CM; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
    Cancer Res; 2020 Jan; 80(1):30-43. PubMed ID: 31694905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
    Li T; Mehraein-Ghomi F; Forbes ME; Namjoshi SV; Ballard EA; Song Q; Chou PC; Wang X; Parker Kerrigan BC; Lang FF; Lesser G; Debinski W; Yang X; Zhang W
    Mol Ther; 2022 Apr; 30(4):1610-1627. PubMed ID: 35151844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGFR2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis.
    Guo M; Zhang J; Han J; Hu Y; Ni H; Yuan J; Sun Y; Liu M; Gao L; Liao W; Ma C; Liu Y; Li S; Li N
    J Transl Med; 2024 May; 22(1):419. PubMed ID: 38702818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
    Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
    J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
    Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
    Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Anti-Warburg Effect Elicited by the cAMP-PGC1α Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes.
    Xing F; Luan Y; Cai J; Wu S; Mai J; Gu J; Zhang H; Li K; Lin Y; Xiao X; Liang J; Li Y; Chen W; Tan Y; Sheng L; Lu B; Lu W; Gao M; Qiu P; Su X; Yin W; Hu J; Chen Z; Sai K; Wang J; Chen F; Chen Y; Zhu S; Liu D; Cheng S; Xie Z; Zhu W; Yan G
    Cell Rep; 2017 Jan; 18(2):468-481. PubMed ID: 28076790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Satoh Y; Ishii N; Aoki M
    Mol Cancer Ther; 2015 Mar; 14(3):704-12. PubMed ID: 25589496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
    Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
    Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
    Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
    Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
    Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
    PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
    Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
    Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
    Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
    Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR3-TACC3 fusion in solid tumors: mini review.
    Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
    Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.